BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36037976)

  • 1. pH-sensitive nanomedicine of novel tubulin polymerization inhibitor for lung metastatic melanoma.
    Bhattarai RS; Bariwal J; Kumar V; Hao C; Deng S; Li W; Mahato RI
    J Control Release; 2022 Oct; 350():569-583. PubMed ID: 36037976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SB226, an inhibitor of tubulin polymerization, inhibits paclitaxel-resistant melanoma growth and spontaneous metastasis.
    Deng S; Banerjee S; Chen H; Pochampally S; Wang Y; Yun MK; White SW; Parmar K; Meibohm B; Hartman KL; Wu Z; Miller DD; Li W
    Cancer Lett; 2023 Feb; 555():216046. PubMed ID: 36596380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymer conjugate of a microtubule destabilizer inhibits lung metastatic melanoma.
    Yang R; Mondal G; Ness RA; Arnst K; Mundra V; Miller DD; Li W; Mahato RI
    J Control Release; 2017 Mar; 249():32-41. PubMed ID: 28130039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic delivery of nanoparticle formulation of novel tubulin inhibitor for treating metastatic melanoma.
    Mundra V; Peng Y; Kumar V; Li W; Miller DD; Mahato RI
    Drug Deliv Transl Res; 2015 Jun; 5(3):199-208. PubMed ID: 25924699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoparticulate delivery of potent microtubule inhibitor for metastatic melanoma treatment.
    Bariwal J; Kumar V; Chen H; Bhattarai RS; Peng Y; Li W; Mahato RI
    J Control Release; 2019 Sep; 309():231-243. PubMed ID: 31330213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colchicine-Binding Site Agent CH-2-77 as a Potent Tubulin Inhibitor Suppressing Triple-Negative Breast Cancer.
    Deng S; Krutilina RI; Hartman KL; Chen H; Parke DN; Wang R; Mahmud F; Ma D; Lukka PB; Meibohm B; Seagroves TN; Miller DD; Li W
    Mol Cancer Ther; 2022 Jul; 21(7):1103-1114. PubMed ID: 35499388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoformulation design and therapeutic potential of a novel tubulin inhibitor in pancreatic cancer.
    Bhattarai RS; Kumar V; Romanova S; Bariwal J; Chen H; Deng S; Bhatt VR; Bronich T; Li W; Mahato RI
    J Control Release; 2021 Jan; 329():585-597. PubMed ID: 33010334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel tubulin inhibitor, 6h, suppresses tumor-associated angiogenesis and shows potent antitumor activity against non-small cell lung cancers.
    Liu Z; Huang L; Zhou T; Chang X; Yang Y; Shi Y; Hao M; Li Z; Wu Y; Guan Q; Zhang W; Zuo D
    J Biol Chem; 2022 Jul; 298(7):102063. PubMed ID: 35618020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel tubulin polymerization inhibitors overcome multidrug resistance and reduce melanoma lung metastasis.
    Wang Z; Chen J; Wang J; Ahn S; Li CM; Lu Y; Loveless VS; Dalton JT; Miller DD; Li W
    Pharm Res; 2012 Nov; 29(11):3040-52. PubMed ID: 22410804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane.
    Feng Z; Zhao G; Yu L; Gough D; Howell SB
    Cancer Chemother Pharmacol; 2010 Apr; 65(5):923-30. PubMed ID: 19685054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity.
    Du T; Lin S; Ji M; Xue N; Liu Y; Zhang Z; Zhang K; Zhang J; Zhang Y; Wang Q; Sheng L; Li Y; Lu D; Chen X; Xu H
    Cancer Lett; 2020 Dec; 495():22-32. PubMed ID: 32931884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation and characterization of paclitaxel palmitate albumin nanoparticles with high loading efficacy: an in vitro and in vivo anti-tumor study in mouse models.
    Chen H; Huang S; Wang H; Chen X; Zhang H; Xu Y; Fan W; Pan Y; Wen Q; Lin Z; Wang X; Gu Y; Ding B; Chen J; Wu X
    Drug Deliv; 2021 Dec; 28(1):1067-1079. PubMed ID: 34109887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary Delivery of Reactive Oxygen Species/Glutathione-Responsive Paclitaxel Dimeric Nanoparticles Improved Therapeutic Indices against Metastatic Lung Cancer.
    Tian X; Bera H; Guo X; Xu R; Sun J; He Z; Cun D; Yang M
    ACS Appl Mater Interfaces; 2021 Dec; 13(48):56858-56872. PubMed ID: 34806372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and bioevaluation of pyrazolo[1,5-a]pyrimidine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site with potent anticancer activities.
    Li G; Wang Y; Li L; Ren Y; Deng X; Liu J; Wang W; Luo M; Liu S; Chen J
    Eur J Med Chem; 2020 Sep; 202():112519. PubMed ID: 32650183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Design, Synthesis, and Biological Activities of Pyrrole-Based Carboxamides: The Novel Tubulin Inhibitors Targeting the Colchicine-Binding Site.
    Boichuk S; Galembikova A; Syuzov K; Dunaev P; Bikinieva F; Aukhadieva A; Zykova S; Igidov N; Gankova K; Novikova M; Kopnin P
    Molecules; 2021 Sep; 26(19):. PubMed ID: 34641324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site.
    Lai Q; Wang Y; Wang R; Lai W; Tang L; Tao Y; Liu Y; Zhang R; Huang L; Xiang H; Zeng S; Gou L; Chen H; Yao Y; Yang J
    Eur J Med Chem; 2018 Aug; 156():162-179. PubMed ID: 30006162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel-loaded biodegradable ROS-sensitive nanoparticles for cancer therapy.
    Pandya AD; Jäger E; Bagheri Fam S; Höcherl A; Jäger A; Sincari V; Nyström B; Štěpánek P; Skotland T; Sandvig K; Hrubý M; Mælandsmo GM
    Int J Nanomedicine; 2019; 14():6269-6285. PubMed ID: 31496685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulation and characterization of polyester/polycarbonate nanoparticles for delivery of a novel microtubule destabilizing agent.
    Mundra V; Lu Y; Danquah M; Li W; Miller DD; Mahato RI
    Pharm Res; 2012 Nov; 29(11):3064-74. PubMed ID: 23054088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance.
    Arnst KE; Wang Y; Hwang DJ; Xue Y; Costello T; Hamilton D; Chen Q; Yang J; Park F; Dalton JT; Miller DD; Li W
    Cancer Res; 2018 Jan; 78(1):265-277. PubMed ID: 29180476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SKLB060 Reversibly Binds to Colchicine Site of Tubulin and Possesses Efficacy in Multidrug-Resistant Cell Lines.
    Yan W; Yang T; Yang J; Wang T; Yu Y; Wang Y; Chen Q; Bai P; Li D; Ye H; Qiu Q; Zhou Y; Hu Y; Yang S; Wei Y; Li W; Chen L
    Cell Physiol Biochem; 2018; 47(2):489-504. PubMed ID: 29794416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.